{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T17:11:38Z","timestamp":1744218698698,"version":"3.37.3"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2016,3,1]],"date-time":"2016-03-01T00:00:00Z","timestamp":1456790400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2016,3,1]],"date-time":"2016-03-01T00:00:00Z","timestamp":1456790400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["R01 HL089758","R01 HL089901"],"award-info":[{"award-number":["R01 HL089758","R01 HL089901"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Treat Options in Rheum"],"published-print":{"date-parts":[[2016,3]]},"DOI":"10.1007\/s40674-016-0040-0","type":"journal-article","created":{"date-parts":[[2016,3,11]],"date-time":"2016-03-11T03:08:43Z","timestamp":1457665723000},"page":"49-60","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Management of Widespread Skin Thickening in Diffuse Systemic Sclerosis"],"prefix":"10.1007","volume":"2","author":[{"given":"Suzanne","family":"Kafaja","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philip","family":"Clements","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,3,11]]},"reference":[{"issue":"11","key":"40_CR1","doi-asserted-by":"publisher","first-page":"2445","DOI":"10.1002\/1529-0131(200011)43:11<2445::AID-ANR11>3.0.CO;2-Q","volume":"43","author":"PJ Clements","year":"2000","unstructured":"Clements PJ, Hurwitz EL, Wong WK, Seibold JR, Mayes M, White B, et al. Skin thickness score as a predictor and correlate of outcome in systemic sclerosis: high-dose versus low-dose penicillamine trial. Arthritis Rheum. 2000;43(11):2445\u201354.","journal-title":"Arthritis Rheum"},{"issue":"3","key":"40_CR2","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1002\/1529-0131(200103)44:3<653::AID-ANR114>3.0.CO;2-Q","volume":"44","author":"PJ Clements","year":"2001","unstructured":"Clements PJ, Wong WK, Hurwitz EL, Furst DE, Mayes M, White B, et al. The Disability Index of the Health Assessment Questionnaire is a predictor and correlate of outcome in the high-dose versus low-dose penicillamine in systemic sclerosis trial. Arthritis Rheum. 2001;44(3):653\u201361.","journal-title":"Arthritis Rheum"},{"issue":"3","key":"40_CR3","doi-asserted-by":"publisher","first-page":"R111","DOI":"10.1186\/ar4562","volume":"16","author":"KJ Bhansing","year":"2014","unstructured":"Bhansing KJ, Lammens M, Knaapen HK, van Riel PL, van Engelen BG, Vonk MC. Scleroderma-polymyositis overlap syndrome versus idiopathic polymyositis and systemic sclerosis: a descriptive study on clinical features and myopathology. Arthritis Res Ther. 2014;16(3):R111.","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"40_CR4","first-page":"14","volume":"13","author":"A Balbir-Gurman","year":"2011","unstructured":"Balbir-Gurman A, Braun-Moscovici Y. Scleroderma overlap syndrome. Isr Med Assoc J. 2011;13(1):14\u201320.","journal-title":"Isr Med Assoc J"},{"issue":"9","key":"40_CR5","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1002\/art.1780370903","volume":"37","author":"VD Steen","year":"1994","unstructured":"Steen VD, Conte C, Owens GR, Medsger Jr TA. Severe restrictive lung disease in systemic sclerosis. Arthritis Rheum. 1994;37(9):1283\u20139.","journal-title":"Arthritis Rheum"},{"key":"40_CR6","doi-asserted-by":"publisher","first-page":"1488","DOI":"10.3899\/jrheum.091165","volume":"37","author":"J Avouac","year":"2010","unstructured":"Avouac J, Walker U, Tyndall A, et al. Characteristics of joint involvement and relationships with systemic inflammation in systemic sclerosis: results from the EULAR Scleroderma Trial and Research Group (EUSTAR) database. J Rheumatol. 2010;37:1488\u2013501.","journal-title":"J Rheumatol"},{"issue":"5","key":"40_CR7","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1093\/rheumatology\/kep464","volume":"49","author":"PP Khanna","year":"2010","unstructured":"Khanna PP, Furst DE, Clements PJ, Maranian P, Indulkar L, Khanna D, et al. Tendon friction rubs in early diffuse systemic sclerosis: prevalence, characteristics and longitudinal changes in a randomized controlled trial. Rheumatology (Oxford). 2010;49(5):955\u20139.","journal-title":"Rheumatology (Oxford)"},{"issue":"9","key":"40_CR8","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.3899\/jrheum.121380","volume":"40","author":"C Muangchan","year":"2013","unstructured":"Muangchan C, Baron M, Pope J, Canadian Scleroderma Research Group. The 15% rule in scleroderma: the frequency of severe organ complications in systemic sclerosis. A systematic review. J Rheumatol. 2013;40(9):1545\u201356.","journal-title":"J Rheumatol"},{"key":"40_CR9","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1002\/acr.20295","volume":"62","author":"JM Grossman","year":"2010","unstructured":"Grossman JM, Gordon R, Ranganath VK, Deal C, Caplan L, Chen W, et al. American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Care Res (Hoboken). 2010;62:1515\u201326.","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"4","key":"40_CR10","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1093\/rheumatology\/35.4.364","volume":"35","author":"FH Van den Hoogen","year":"1996","unstructured":"Van den Hoogen FH, Boerbooms AM, Swaak AJ, Rasker JJ, van Lier HJ, van de Putte LB. Comparison of methotrexate with placebo in the treatment of systemic sclerosis: a 24 week randomized double-blind trial, followed by a 24 week observational trial. Br J Rheumatol. 1996;35(4):364\u201372.","journal-title":"Br J Rheumatol"},{"issue":"6","key":"40_CR11","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1002\/1529-0131(200106)44:6<1351::AID-ART227>3.0.CO;2-I","volume":"44","author":"JE Pope","year":"2001","unstructured":"Pope JE, Bellamy N, Seibold JR, Baron M, Ellman M, Carette S, et al. A randomized, controlled trial of methotrexate versus placebo in early diffuse scleroderma. Arthritis Rheum. 2001;44(6):1351\u20138.","journal-title":"Arthritis Rheum"},{"issue":"12","key":"40_CR12","doi-asserted-by":"publisher","first-page":"3962","DOI":"10.1002\/art.22204","volume":"54","author":"RK Hoyles","year":"2006","unstructured":"Hoyles RK, Ellis RW, Wellsbury J, Lees B, Newlands P, Goh NS, et al. A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma. Arthritis Rheum. 2006;54(12):3962\u201370.","journal-title":"Arthritis Rheum"},{"issue":"25","key":"40_CR13","doi-asserted-by":"publisher","first-page":"2655","DOI":"10.1056\/NEJMoa055120","volume":"354","author":"DP Tashkin","year":"2006","unstructured":"Tashkin DP, Elashoff R, Clements PJ, Goldin J, Roth MD, Furst DE, et al. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med. 2006;354(25):2655\u201366.","journal-title":"N Engl J Med"},{"issue":"24","key":"40_CR14","doi-asserted-by":"publisher","first-page":"2490","DOI":"10.1001\/jama.2014.6368","volume":"311","author":"JM Van Laar","year":"2014","unstructured":"Van Laar JM, Farge D, Sont JK, Naraghi K, Marjanovic Z, Larghero J, et al. Autologous hematopoietic stem cell transplantation vs intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis: a randomized clinical trial. JAMA. 2014;311(24):2490\u20138. The ASTIS trial is the first randomized controlled trial of autologous stem cell transplantation versus monthly intravenous cyclophosphamide for 12 months in the treatment of early diffuse SSc. The results showed statistically significant improvements in decreasing skin thickness, halting\/slowing the progression of ILD, improving function (DHAQ-DI), and improving the physical component of the SF-36 in the subjects who received autologous stem cell transplantation compared to subjects who received cyclophosphamide.","journal-title":"JAMA"},{"issue":"2","key":"40_CR15","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1093\/rheumatology\/kep093","volume":"49","author":"D Daoussis","year":"2010","unstructured":"Daoussis D, Liossis SN, Tsamandas AC, Kalogeropoulou C, Kazantzi A, Sirinian C, et al. Experience with rituximab in scleroderma: results from a 1-year, proof-of-principle study. Rheumatology (Oxford). 2010;49(2):271\u201380.","journal-title":"Rheumatology (Oxford)"},{"key":"40_CR16","unstructured":"Clements PJ, Tashkin D, Roth M, Khanna D, Furst DE, Tseng CH, et al. The Scleroderma Lung Study II (SLS II) shows that both oral cyclophosphamide (CYC) and mycophenolate Mofitil (MMF) are efficacious in treating progressive interstitial lung disease (ILD) in patients with systemic cclerosis (SSc). Abstract, 2015 ACR Annual Meeting, San Francisco, CA. oral presentation. 1075"},{"key":"40_CR17","doi-asserted-by":"crossref","unstructured":"Tashkin D, Roth M, Clements P, Furst D, Khanna D, Goldin J, et al. Efficacy and safety of mycophenolate (MMF) vs oral cyclophosphamide (CYC) for treatment of scleroderma-interstitial lung disease (SSc-ILD): results of Scleroderma Lung Study II. Chest J Chest. 2015, Vol 148, Meeting abstracts 2015). Scleroderma Lung Study II showed that 2 years of oral mycophenolate mofitil (MMF) stabilized or improved lung physiology, decreased dyspnea and decreased thickened \/ indurated skin in early SSc to the same degree as one year of oral cyclophosphamide (CYC). MMF was also better tolerated than CYC while the only significant difference in adverse effect profile lay in thrombocytopenia that was seen predominantly in CYC patients.","DOI":"10.1378\/chest.2331164"},{"key":"40_CR18","unstructured":"Khanna D, Denton C, Van Laar JM, Jahreis A, Cheng S, Spotswood H, et al. Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis: week 24 data from a phase 2\/3 trial. Abstract, Meeting: 2014 ACR\/ARHP Annual Meeting. 2014"},{"key":"40_CR19","doi-asserted-by":"crossref","unstructured":"Khanna D, Denton CP, Jahreis A, Van Laar JM, Cheng S, Spotswood H, et al. Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis: week 48 data from the FASSCINATE Trial. Abstract, EULAR 2015. The use of subcutaneous tocilizumab (TCZ) was tested in a double-blind, randomized placebo-controlled trial in diffuse SSc. The results showed strong trends for improvement in cutaneous induration and lung physiology in the TCZ arm compared to the placebo arm in this 48-week trial.","DOI":"10.1136\/annrheumdis-2015-eular.2281"},{"issue":"3","key":"40_CR20","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1002\/art.20195","volume":"50","author":"Y Levy","year":"2004","unstructured":"Levy Y, Amital H, Langevitz P, Nacci F, Righi A, Conforti L, et al. Intravenous immunoglobulin modulates cutaneous involvement and reduces skin fibrosis in systemic sclerosis: an open-label study. Arthritis Rheum. 2004;50(3):1005\u20137. No abstract available.","journal-title":"Arthritis Rheum"},{"issue":"1","key":"40_CR21","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1136\/ard.2009.127621","volume":"70","author":"RT Domsic","year":"2011","unstructured":"Domsic RT, Rodriguez-Reyna T, Lucas M, Fertig N, Medsger Jr TA. Skin thickness progression rate: a predictor of mortality and early internal organ involvement in diffuse scleroderma. Ann Rheum Dis. 2011;70(1):104\u20139.","journal-title":"Ann Rheum Dis"},{"issue":"4 Suppl 91","key":"40_CR22","first-page":"S111","volume":"33","author":"OA Moore","year":"2015","unstructured":"Moore OA, Proudman SM, Goh N, Corte TJ, Rouse H, Hennessy O, et al. Quantifying change in pulmonary function as a prognostic marker in systemic sclerosis-related interstitial lung disease. Clin Exp Rheumatol. 2015;33(4 Suppl 91):S111\u20136. In this study, it was shown that declines in %forced vital capacity \u226510% or in %diffusing capacity for carbon monoxide \u226515% over 1\u00a0year of follow-up were predictive of progressive interstitial lung disease in SSc.","journal-title":"Clin Exp Rheumatol"},{"issue":"27","key":"40_CR23","doi-asserted-by":"publisher","first-page":"1993","DOI":"10.1056\/NEJM199312303292704","volume":"329","author":"G Ruiz-Irastorza","year":"1993","unstructured":"Ruiz-Irastorza G, Khamashta M, Dalakas MC, Illa I, Dambrosia JM, Soueidan SA, et al. Pregnancy and rheumatic disease. ACR website 2014. A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis. N Engl J Med. 1993;329(27):1993\u20132000.","journal-title":"N Engl J Med"},{"issue":"27","key":"40_CR24","doi-asserted-by":"publisher","first-page":"1993","DOI":"10.1056\/NEJM199312303292704","volume":"329","author":"MC Dalakas","year":"1993","unstructured":"Dalakas MC, Illa I, Dambrosia JM, Soueidan SA, Stein DP, Otero C, et al. A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis. N Engl J Med. 1993;329(27):1993\u20132000.","journal-title":"N Engl J Med"},{"key":"40_CR25","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.semarthrit.2012.01.003","volume":"42","author":"KM Walker","year":"2012","unstructured":"Walker KM, Pope J. Participating members of the Scleroderma Clinical Trials Consortium (SCTC), Canadian Scleroderma Research Group. Treatment of systemic sclerosis complications: what to use when first-line treatment fails\u2014a consensus of systemic sclerosis experts. Semin Arthritis Rheum. 2012;42:42\u201355. This was not a scientific study of the practices of scleroderma experts from around the world. Rather, it was the questioning of physicians of what the physicians themselves thought about how they treated polyarthritis and other musculoskeletal manifestations as they occur in systemic sclerosis.","journal-title":"Semin Arthritis Rheum"},{"key":"40_CR26","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1016\/j.semarthrit.2011.10.003","volume":"41","author":"PJ Clements","year":"2012","unstructured":"Clements PJ, Allanore Y, Khanna D, Singh M, Furst DE. Arthritis in systemic sclerosis: systematic review of the literature and suggestions for the performance of future clinical trials in systemic sclerosis arthritis. Semin Arthritis Rheum. 2012;41:801\u201314. This systematic literature review revealed that there was very little in the way of systematically performed studies of outcomes or of therapies that could impact polyarthritis or other musculoskeletal manifestation of systemic sclerosis.","journal-title":"Semin Arthritis Rheum"},{"issue":"Suppl. 58","key":"40_CR27","first-page":"S42","volume":"28","author":"M Baron","year":"2010","unstructured":"Baron M, Bernier P, Cote F, DeLegge MH, Falovitch G, Friedman G, et al. Screening and management of malnutrition and related gastro-intestinal disorders in systemic sclerosis: recommendations of a North American expert panel. Clin Exp Rheumatol. 2010;28 Suppl 58:S42\u20136.","journal-title":"Clin Exp Rheumatol"},{"issue":"1","key":"40_CR28","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1093\/rheumatology\/36.1.86","volume":"36","author":"RA Hamilton","year":"1997","unstructured":"Hamilton RA, Kremer JM. Why intramuscular methotrexate may be more efficacious than oral dosing in patients with rheumatoid arthritis. Br J Rheumatol. 1997;36(1):86\u201390.","journal-title":"Br J Rheumatol"},{"issue":"1","key":"40_CR29","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1002\/art.25061","volume":"62","author":"PA Monach","year":"2010","unstructured":"Monach PA, Arnold LM, Merkel PA. Incidence and prevention of bladder toxicity from cyclophosphamide in the treatment of rheumatic diseases: a data-driven review. Arthritis Rheum. 2010;62(1):9\u201321.","journal-title":"Arthritis Rheum"}],"container-title":["Current Treatment Options in Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40674-016-0040-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40674-016-0040-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40674-016-0040-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40674-016-0040-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,16]],"date-time":"2020-05-16T23:49:50Z","timestamp":1589672990000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40674-016-0040-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,3]]}},"alternative-id":["40"],"URL":"https:\/\/doi.org\/10.1007\/s40674-016-0040-0","relation":{},"ISSN":["2198-6002"],"issn-type":[{"type":"electronic","value":"2198-6002"}],"subject":[],"published":{"date-parts":[[2016,3]]},"assertion":[{"value":"11 March 2016","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"This work was supported by grants from the NHLBI\/NIH: R01 HL089758 and R01 HL089901.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Suzanne Kafaja declares that she has no conflict of interest. Philip Clements declares that he has no conflict of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by the authors.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}